Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 11/20 | 0.47 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4363002 | 0.85 | KIF11 (0.49) | KIF11KCNN4KCNH2CA4LTA4H | |
| SCHEMBL12225852 | 0.85 | KIF11 (0.49) | KIF11KCNN4KCNH2CA4LTA4H | |
| SCHEMBL319646 | 0.84 | KIF11 (0.63) | KIF11KCNN4IDO1 | |
| SCHEMBL6746344 | 0.84 | KIF11 (0.71) | KIF11KCNN4KCNH2CA4LTA4H | |
| SCHEMBL6746389 | 0.84 | KIF11 (0.71) | KIF11KCNN4KCNH2CA4LTA4H | |
| SCHEMBL18409776 | 0.83 | KCNN4 (0.49) | KIF11KCNN4KCNH2CA4LTA4H | |
| SCHEMBL5391076 | 0.81 | KIF11 (0.61) | KIF11KCNN4KCNH2DRD2DRD4 | |
| SCHEMBL9439820 | 0.81 | KIF11 (0.47) | KIF11KCNN4KCNH2DRD2DRD4 | |
| SCHEMBL6751128 | 0.80 | KIF11 (0.44) | KIF11KCNN4KCNH2CA4LTA4H | |
| SCHEMBL10276699 | 0.80 | KIF11 (0.46) | KIF11LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622572-B1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | SIRNA THERAPEUTICS INC (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-3231445-A1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | Sirna Therapeutics, Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-3222294-A1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | Sirna Therapeutics, Inc. (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-2415486-B1 | Conjugates and compositions for cellular delivery | SIRNA THERAPEUTICS INC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-8461313-B2 | Conjugates and compositions for cellular delivery | SIRNA THERAPEUTICS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120202983-A1 | Conjugates and Compositions for Cellular Delivery | SIRNA THERAPEUTICS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8188247-B2 | Conjugates and compositions for cellular delivery | SIRNA THERAPEUTICS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2415486-A2 | Conjugates and compositions for cellular delivery | Sirna Therapeutics, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| US-7964578-B2 | Conjugates and compositions for cellular delivery | SIRNA THERAPEUTICS, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20110124853-A1 | Conjugates and Compositions for Cellular Delivery | CHEN TONGQIAN | 2011-05-26 | — | — | US | disclosed |
| US-7491805-B2 | Biological conjugates used for drug delivery; side effect reduction | SIRNA THERAPEUTICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7109165-B2 | Conjugates and compositions for cellular delivery | SIRNA THERAPEUTICS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1622572-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | Sirna Therapeutics, Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20050239739-A1 | Conjugates and compositions for cellular delivery | SIRNA THERAPEUTICS, INC. | 2005-10-27 | — | — | US | disclosed |
| EP-1572067-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | Sirna Therapeutics, Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005041859-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY. | SIRNA THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20040249178-A1 | Biological conjugates used for drug delivery; side effect reduction | SIRNA THERAPEUTICS, INC. (US) | 2004-12-09 | — | — | US | disclosed |
| US-20040110296-A1 | biological conjugates used for drug delivery; side effect reduction | RIBOZYME PHARMACEUTICALS, INC. | 2004-06-10 | — | — | US | disclosed |
| US-20030104985-A1 | Conjugates and compositions for cellular delivery | BANK OF AMERICA, N.A. | 2003-06-05 | — | — | US | disclosed |
| WO-2002094185-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239739-A1 | Conjugates and compositions for cellular delivery | MTHFD1, FOLR1, FOLR2 | KIF11 635/4885KCNN4 4852/4885KCNH2 4751/4885 |
| US-20110124853-A1 | Conjugates and Compositions for Cellular Delivery | ALB, PHAX, HEXA | KIF11 1686/4885KCNN4 4565/4885KCNH2 4800/4885 |
| US-20030104985-A1 | Conjugates and compositions for cellular delivery | MTHFD1, FOLR1, FOLR2 | KIF11 635/4885KCNN4 4852/4885KCNH2 4751/4885 |
| US-20120202983-A1 | Conjugates and Compositions for Cellular Delivery | MTHFD1, FOLR1, FOLR2 | KIF11 635/4885KCNN4 4852/4885KCNH2 4751/4885 |
| US-20040249178-A1 | Biological conjugates used for drug delivery; side effect reduction | ALB, HEXA, ADAR | KIF11 1312/4885KCNN4 4421/4885KCNH2 4792/4885 |
| US-20040110296-A1 | biological conjugates used for drug delivery; side effect reduction | ALB, HEXA, ADAR | KIF11 1312/4885KCNN4 4421/4885KCNH2 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.